The interaction potential of herbal medicinal products: a luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil's claw (Harpagophyti radix) preparations
Open Access
- 8 February 2011
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 63 (3) , 429-438
Abstract
Objectives: Potential interactions between herbal medicinal products and the cytochrome (CYP) P450 system are an important safety concern. We set out to develop a screening panel for assessing such interactions and use it to evaluate the interaction potential of devil's claw. Methods: The panel consisted of luminescence-based inhibition assays for CYP1A2, 2C9, 2C19, 2D6 and 3A4, and a reporter gene (luciferase) assay for pregnane X receptor (PXR) activation and CYP3A4 induction. Caftaric acid and chlorogenic acid, two compounds with strong fluorescence quenching properties, were used to demonstrate the assay's resistance to interference. We tested 10 commercial devil's claw preparations as well as harpagoside and harpagide, two important constituents of devil's claw. Key findings: Five preparations were found to weakly inhibit CYP3A4 (IC50 124.2–327.6 µg/ml) and five were found to weakly activate PXR (EC50 10.21–169.3 µg/ml). Harpagoside and harpagide did not inhibit CYP3A4. In agreement with published data, bergamottin, a natural product known to interact with CYP3A4, was shown to inhibit CYP3A4 with an IC50 of 13.63 µm and activate PXR with an EC50 of 6.7 µm. Conclusions: Devil's claw preparations are unlikely to have a clinically relevant effect on CYP function. The assay panel proved effective in screening devil's claw preparations, demonstrating its suitability for use with plant extracts. It showed superior sensitivity and resistance to interference.Keywords
This publication has 26 references indexed in Scilit:
- Safety of Herbal Medicinal Products: Echinacea and Selected Alkylamides Do Not Induce CYP3A4 mRNA ExpressionEvidence-Based Complementary and Alternative Medicine, 2011
- Interactions Between Herbal Medicines and Prescribed DrugsDrugs, 2009
- Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide contentJournal of Pharmacy and Pharmacology, 2007
- Luminogenic cytochrome P450 assaysExpert Opinion on Drug Metabolism & Toxicology, 2006
- A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticidesBiochemical Pharmacology, 2004
- Drug Interactions Between Herbal and Prescription MedicinesDrug Safety, 2003
- The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic MetabolismEndocrine Reviews, 2002
- Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin® in patients with pain in the lower back, knee or hipPhytomedicine, 2002
- Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural productsPhytomedicine, 2002
- Inhibition of TNF-α synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69Phytomedicine, 2001